Protein-Losing Enteropathy in Canine IBD: Clinical Insights, Diagnostic Challenges, and Practical Management Strategies

Protein-losing enteropathy (PLE) remains one of the most clinically challenging consequences of chronic gastrointestinal disease in dogs, particularly when associated with inflammatory bowel disease (IBD). While many canine IBD cases respond favorably to dietary and immunosuppressive therapy, progression to PLE significantly complicates long-term management and prognosis. 

In canine patients, PLE develops secondary to disruptions in intestinal integrity and lymphatic function. Obstructed intestinal lymphatic drainage can lead to leakage of lymph into the intestinal lumen, resulting in substantial loss of serum proteins, especially albumin. Increased intestinal vascular permeability may similarly permit plasma proteins to extravasate into the gut lumen^1,2. Chronic inflammatory disorders such as IBD are among the most common underlying causes. 

Understanding the Clinical Spectrum of Canine IBD 

Inflammatory bowel disease is considered an idiopathic, immune-mediated gastrointestinal disorder characterized by persistent or recurrent vomiting, diarrhea, and weight loss^1,3. Depending on disease distribution, lesions may remain localized to the small intestine or involve diffuse segments of the gastrointestinal tract. Histopathologically, lymphoplasmacytic enteritis is most frequently identified, although eosinophilic and granulomatous variants can occur¹. 

For practicing veterinarians, recognizing the subtle transition from uncomplicated IBD to PLE is critical. Dogs may initially present with chronic soft stools or intermittent vomiting, but progressive hypoalbuminemia can lead to more severe complications, including ascites due to reduced oncotic pressure. Melena or hematochezia may also develop depending on lesion severity and location¹. 

Laboratory abnormalities are often supportive rather than diagnostic. Hypoalbuminemia, hypoglobulinemia, and hypocholesterolemia commonly reflect impaired mucosal absorption and concurrent lymphangiectasia¹. Hypocobalaminemia is another important finding that should not be overlooked, as it may worsen gastrointestinal dysfunction and negatively affect treatment response. 

Imaging and Histopathology: Moving Beyond Nonspecific Findings 

Radiography frequently yields limited diagnostic information in canine IBD cases. In contrast, abdominal ultrasonography can provide clinically valuable insight, particularly when intestinal wall thickening or characteristic mucosal striations suggest concurrent lymphangiectasia^1,4. 

Despite advances in imaging, definitive diagnosis still relies on histopathologic confirmation through intestinal biopsy¹. This becomes particularly important in patients with focal intestinal lesions, where differentiation between inflammatory disease and neoplasia directly impacts therapeutic decisions. 

Clinically, veterinarians should remain cautious when a previously stable IBD patient demonstrates sudden worsening of hypoalbuminemia, poor response to corticosteroids, or emergence of focal intestinal abnormalities on imaging. These cases warrant more aggressive diagnostic investigation. 

Practical Approaches to Medical Management 

Management of canine IBD-associated PLE remains centered on multimodal medical therapy. Dietary modification is often the first-line intervention, with some mild cases achieving remission through nutrition alone^1,5. Highly digestible or novel protein diets continue to play a major role in reducing antigenic stimulation and intestinal inflammation. 

For moderate to severe disease, corticosteroids such as prednisolone or prednisone remain the cornerstone of immunomodulatory therapy, commonly initiated at 1 to 2 mg/kg q12h with gradual tapering over 3 to 4 weeks based on clinical response¹. However, prolonged steroid exposure requires careful monitoring for adverse effects. 

In refractory patients, adjunctive immunosuppressive agents including azathioprine, cyclosporine, or mycophenolate mofetil, may be necessary. Monitoring for drug-related toxicity becomes especially important in small-breed or geriatric dogs with chronic disease¹. 

Adjunctive therapies also deserve attention in day-to-day clinical practice. Probiotics and prebiotics may provide anti-inflammatory benefits through modulation of the intestinal microbiota, while cobalamin supplementation is indicated in documented hypocobalaminemia¹. Increasingly, clinicians are also considering fecal microbial transplantation in difficult cases where conventional therapies fail. 

When Medical Therapy Is Not Enough 

Although surgical intervention is generally not recommended as standard therapy for canine IBD, severe focal inflammatory lesions may occasionally alter the clinical approach. Surgery should never replace comprehensive medical management, but in selected refractory cases, surgical biopsy or segmental resection may provide both diagnostic clarification and clinical improvement. 

However, clinicians must carefully weigh the risks of intestinal surgery, including malabsorption, bile acid dysregulation, septic complications, leakage, and postoperative diarrhea. Because canine IBD is often diffuse rather than segmental, surgery should remain a last-resort consideration rather than a primary therapeutic strategy^1,6. 

Ultimately, successful management of canine PLE secondary to IBD depends on early recognition, aggressive nutritional support, individualized immunomodulation, and vigilant long-term monitoring of albumin trends and gastrointestinal signs. 

Reference 

1. Ha JH, Jeong Y, Kwak HH, Choi S, Ahn JO, Chung JY. Prognosis for surgical intestinal resection in inflammatory bowel disease refractory to medical treatment in a dog. The Canadian Veterinary Journal. 2025 Dec 1;66(12):1303-7. https://pmc.ncbi.nlm.nih.gov/articles/PMC12825713/ 

2. Craven MD, Washabau RJ. Comparative pathophysiology and management of protein-losing enteropathy. Journal of veterinary internal medicine. 2019 Mar;33(2):383-402. https://academic.oup.com/jvim/article/33/2/383/8448101 

3. Carrasco V, Rodríguez-Bertos A, Rodríguez-Franco F, Wise AG, Maes R, Mullaney T, Kiupel M. Distinguishing intestinal lymphoma from inflammatory bowel disease in canine duodenal endoscopic biopsy samples. Veterinary Pathology. 2015 Jul;52(4):668-75. https://journals.sagepub.com/doi/pdf/10.1177/0300985814559398 

4. Linta N, Pey P, Baron Toaldo M, Pietra M, Felici M, Bettini G, Cipone M, Diana A. Contrast-enhanced ultrasonography in dogs with inflammatory bowel disease. Journal of veterinary internal medicine. 2021 Sep;35(5):2167-76. https://academic.oup.com/jvim/article-pdf/35/5/2167/66672966/jvim16202.pdf 

5. Green J, Kathrani A. Incidence of relapse of inflammatory protein-losing enteropathy in dogs and associated risk factors. Journal of veterinary internal medicine. 2022 Nov;36(6):1981-8. https://academic.oup.com/jvim/article-pdf/36/6/1981/66666764/jvim16561.pdf 

6. Zhang R, Ray JW, Jain MK, Han S. Ileectomy-induced bile overaccumulation in mouse intestine. Journal of Visualized Experiments: JoVE. 2017 Aug 21(126):55728. https://pmc.ncbi.nlm.nih.gov/articles/PMC5614358/pdf/jove-126-55728.pdf